MK6-83 is a selective inhibitor of TNIK (TRAF2- and NCK-interacting kinase), primarily investigated for its potential in oncology research. It modulates the Wnt signaling pathway, which is involved in cell development, proliferation, and tumor formation, particularly in colorectal cancer models. Researchers use MK6-83 to explore mechanisms of drug resistance, evaluate combination therapies with other anticancer agents, and screen new compounds for cancer treatment. Its application remains confined to preclinical research, serving as a tool compound for target validation and pathway analysis in cellular and animal studies.